Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In Vivo Efficacy of Nano Hyaluronan-Conjugated Cisplatin for Treatment of Murine Melanoma</title><author><name sortKey="Yang, Qiuhong" sort="Yang, Qiuhong" uniqKey="Yang Q" first="Qiuhong" last="Yang">Qiuhong Yang</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author><author><name sortKey="Aires, Daniel J" sort="Aires, Daniel J" uniqKey="Aires D" first="Daniel J." last="Aires">Daniel J. Aires</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Cai, Shuang" sort="Cai, Shuang" uniqKey="Cai S" first="Shuang" last="Cai">Shuang Cai</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author><author><name sortKey="Fraga, Garth R" sort="Fraga, Garth R" uniqKey="Fraga G" first="Garth R." last="Fraga">Garth R. Fraga</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Zhang, Da" sort="Zhang, Da" uniqKey="Zhang D" first="Da" last="Zhang">Da Zhang</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Li, Cicy Z" sort="Li, Cicy Z" uniqKey="Li C" first="Cicy Z." last="Li">Cicy Z. Li</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Forrest, M Laird" sort="Forrest, M Laird" uniqKey="Forrest M" first="M. Laird" last="Forrest">M. Laird Forrest</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24595572</idno><idno type="pmc">4344317</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344317</idno><idno type="RBID">PMC:4344317</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">003473</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003473</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">In Vivo Efficacy of Nano Hyaluronan-Conjugated Cisplatin for Treatment of Murine Melanoma</title><author><name sortKey="Yang, Qiuhong" sort="Yang, Qiuhong" uniqKey="Yang Q" first="Qiuhong" last="Yang">Qiuhong Yang</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author><author><name sortKey="Aires, Daniel J" sort="Aires, Daniel J" uniqKey="Aires D" first="Daniel J." last="Aires">Daniel J. Aires</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Cai, Shuang" sort="Cai, Shuang" uniqKey="Cai S" first="Shuang" last="Cai">Shuang Cai</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author><author><name sortKey="Fraga, Garth R" sort="Fraga, Garth R" uniqKey="Fraga G" first="Garth R." last="Fraga">Garth R. Fraga</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Zhang, Da" sort="Zhang, Da" uniqKey="Zhang D" first="Da" last="Zhang">Da Zhang</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Li, Cicy Z" sort="Li, Cicy Z" uniqKey="Li C" first="Cicy Z." last="Li">Cicy Z. Li</name><affiliation><nlm:aff id="A2">University of Kansas Medical Center, Kansas City, KS</nlm:aff></affiliation></author><author><name sortKey="Forrest, M Laird" sort="Forrest, M Laird" uniqKey="Forrest M" first="M. Laird" last="Forrest">M. Laird Forrest</name><affiliation><nlm:aff id="A1">University of Kansas, Lawrence, KS</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of drugs in dermatology : JDD</title><idno type="ISSN">1545-9616</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title><p id="P1">Melanoma is a deadly skin cancer with rapidly rising incidence. While localized melanoma can be treated with excision, there are at present no similarly effective treatments for regional and distant disease, so survival rates are low. One problem is that melanoma is chemo-resistant, and most chemotherapy doses are limited by systemic toxicity. A method for delivering high-dose chemotherapy directly to tumors and draining lymph nodes could have the advantage of allowing much higher effective doses with reduced systemic exposure.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Human melanoma cell line A-2058 tumor cells were injected into athymic mice. After tumors grew to 50~100 mm<sup>3</sup> mice were divided into five groups: (1) nontreated (2) intravenous (i.v.) cisplatin, (3) i.v. nano hyaluronan-conjugated cisplatin (HA-Pt), (4) subcutaneous (s.c.) peri-tumoral cisplatin, and (5) s.c. peri-tumoral HA-Pt. All treatment groups received 3 weekly doses of 10 mg/kg.</p></sec><sec id="S3"><title>Results</title><p id="P3">Tumors grew progressively in all control, i.v. cisplatin, and s.c. cisplatin groups. Tumors showed a trend toward slower growth in the i.v. HA-Pt group, but all animals died or were euthanized per protocol within 3 weeks of treatment. Tumors showed shrinkage only in the subcutaneous peri-tumoral HA-cisplatin group; one of these mice appeared to be cured.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Peri-tumoral HA-cisplatin may be shown potential as a therapeutic option in treatment of certain types of melanoma.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101160020</journal-id><journal-id journal-id-type="pubmed-jr-id">30387</journal-id><journal-id journal-id-type="nlm-ta">J Drugs Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J Drugs Dermatol</journal-id><journal-title-group><journal-title>Journal of drugs in dermatology : JDD</journal-title></journal-title-group><issn pub-type="ppub">1545-9616</issn></journal-meta><article-meta><article-id pub-id-type="pmid">24595572</article-id><article-id pub-id-type="pmc">4344317</article-id><article-id pub-id-type="manuscript">NIHMS553687</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>In Vivo Efficacy of Nano Hyaluronan-Conjugated Cisplatin for Treatment of Murine Melanoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Qiuhong</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A1">a</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Aires</surname><given-names>Daniel J.</given-names></name><degrees>MD, JD</degrees><xref ref-type="aff" rid="A2">b</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Shuang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Fraga</surname><given-names>Garth R.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Da</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Cicy Z.</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>M. Laird</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">a</xref></contrib></contrib-group><aff id="A1"><label>a</label>University of Kansas, Lawrence, KS</aff><aff id="A2"><label>b</label>University of Kansas Medical Center, Kansas City, KS</aff><author-notes><corresp id="FN1">AUTHOR CORRESPONDENCE: M. Laird Forrest PhD, <email>mforrest@ku.edu</email></corresp><fn id="FN2" fn-type="equal"><label>*</label><p>Contributed equally to this article</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>7</day><month>2</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>2</month><year>2015</year></pub-date><volume>13</volume><issue>3</issue><fpage>283</fpage><lpage>287</lpage><permissions><copyright-statement>Copyright © 2014</copyright-statement><copyright-year>2014</copyright-year></permissions><abstract><sec id="S1"><title>Background</title><p id="P1">Melanoma is a deadly skin cancer with rapidly rising incidence. While localized melanoma can be treated with excision, there are at present no similarly effective treatments for regional and distant disease, so survival rates are low. One problem is that melanoma is chemo-resistant, and most chemotherapy doses are limited by systemic toxicity. A method for delivering high-dose chemotherapy directly to tumors and draining lymph nodes could have the advantage of allowing much higher effective doses with reduced systemic exposure.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Human melanoma cell line A-2058 tumor cells were injected into athymic mice. After tumors grew to 50~100 mm<sup>3</sup> mice were divided into five groups: (1) nontreated (2) intravenous (i.v.) cisplatin, (3) i.v. nano hyaluronan-conjugated cisplatin (HA-Pt), (4) subcutaneous (s.c.) peri-tumoral cisplatin, and (5) s.c. peri-tumoral HA-Pt. All treatment groups received 3 weekly doses of 10 mg/kg.</p></sec><sec id="S3"><title>Results</title><p id="P3">Tumors grew progressively in all control, i.v. cisplatin, and s.c. cisplatin groups. Tumors showed a trend toward slower growth in the i.v. HA-Pt group, but all animals died or were euthanized per protocol within 3 weeks of treatment. Tumors showed shrinkage only in the subcutaneous peri-tumoral HA-cisplatin group; one of these mice appeared to be cured.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Peri-tumoral HA-cisplatin may be shown potential as a therapeutic option in treatment of certain types of melanoma.</p></sec></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003473 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 003473 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |